June 2025
1. YAMAMOTO S, Fukuhara H, Kuroiwa H, Shigehisa R, et al
   Preoperative Pyuria as a Predictor of False-Positive Rates in the Photodynamic Diagnosis of Nonmuscle-Invasive Bladder Cancer Using Oral 5-Aminolevulinic Acid.
   Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70134.
   

   >> Share

   
   
2. FUKIAGE Y, Muramoto A, Terada N, Kobayashi M, et al
   Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ.
   Int J Urol. 2025;32:737-746.
   

   >> Share

   
   
3. XU S, Shi H, Yu F, Lu M, et al
   Outcomes of Second Resection Following Conventional Initial Transurethral Resection of Bladder Tumors.
   Int J Urol. 2025;32:720-726.
   

   >> Share

   
   
4. MORGANS AK, Mucha L, Quicquaro C, Shih V, et al
   Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.
   Int J Urol. 2025;32:650-657.
   

   >> Share

   
   
5. OZAKI K, Yamamoto H, Sekine Y, Horiguchi H, et al
   Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study.
   Int J Urol. 2025;32:679-685.
   

   >> Share

   
   May 2025
6. SASAKI D, Yoneyama T, Yoneyama F, Ozaki K, et al
   PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
   Int J Urol. 2025 May 23. doi: 10.1111/iju.70122.
   

   >> Share

   
   
7. MIYAKE M
   Editorial Comment From Dr. Miyake to Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
   Int J Urol. 2025 May 15. doi: 10.1111/iju.70112.
   

   >> Share

   
   
8. AKPINAR C, Suer E, Akdogan B, Izol V, et al
   The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association.
   Int J Urol. 2025;32:508-515.
   

   >> Share

   
   
9. YONEYAMA F, Shinohara M, Kawashima Y, Yoneyama A, et al
   Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
   Int J Urol. 2025 May 1. doi: 10.1111/iju.70087.
   

   >> Share

   
   
10. KOBATAKE K, Goto K, Sakamoto Y, Iwane K, et al
    Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin.
    Int J Urol. 2025;32:524-530.
    

    >> Share

    
    
11. KANNO T, Ito K, Kita Y, Mochizuki T, et al
    Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma.
    Int J Urol. 2025;32:593-597.
    

    >> Share

    
    
12. YAMADA Y, Taguchi M, Shimatani K, Yanagi T, et al
    The usefulness of transarterial embolization before transurethral resection of bladder tumor for patients with large bladder tumors.
    Int J Urol. 2025;32:488-492.
    

    >> Share

    
    
13. WADA N, Hatakeyama T, Takagi H, Tsunekawa R, et al
    Trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor and perioperative complications.
    Int J Urol. 2025;32:516-523.
    

    >> Share

    
    April 2025
14. NAITO R, Izumi K, Takimoto A, Nakagawa R, et al
    Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?
    Int J Urol. 2025 Apr 11. doi: 10.1111/iju.70064.
    

    >> Share

    
    
15. SIMHAL RK, McPartland C, Wang KR, Buck M, et al
    Bowel regimens before radical cystectomy: An analysis of a modern cohort.
    Int J Urol. 2025;32:402-408.
    

    >> Share

    
    March 2025
16. SANO T, Ohe C, Nakamoto T, Yoshida T, et al
    Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of Bladder Cancer According to a History of Intravesical Bacillus Calmette-Guerin Therapy.
    Int J Urol. 2025 Mar 26. doi: 10.1111/iju.70045.
    

    >> Share

    
    
17. YAJIMA S, Hata S, Masumori N, Matsuoka Y, et al
    Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive Bladder Cancer: A Discrete Choice Experiment in Japan.
    Int J Urol. 2025 Mar 10. doi: 10.1111/iju.70032.
    

    >> Share

    
    
18. SAZUKA T
    Editorial Comment to "Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Nonmuscle Invasive Bladder Cancer".
    Int J Urol. 2025 Mar 3. doi: 10.1111/iju.70028.
    

    >> Share

    
    
19. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
    Int J Urol. 2025;32:270-276.
    

    >> Share

    
    February 2025
20. SHINDO T, Ueki Y, Muranaka I, Kobayashi G, et al
    Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2025 Feb 13. doi: 10.1111/iju.70009.
    

    >> Share

    
    
21. HARA S, Fukuokaya W, Miki J, Taoka R, et al
    Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005.
    

    >> Share

    
    January 2025
22. MIYAKE M
    Editorial Comment from Dr Miyake to alpha1-blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 28. doi: 10.1111/iju.15687.
    

    >> Share

    
    
23. SUZUKI C, Minagawa T, Onuma H, Hiragata S, et al
    alpha(1)-Blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15655.
    

    >> Share

    
    December 2024
24. TAOKA R, Fujimoto K, Inoue K, Tsuzuki T, et al
    Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial.
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15653.
    

    >> Share

    
    
25. NAKAMURA Y, Yoshida S, Arita Y, Takeshita R, et al
    The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15638.
    

    >> Share

    
    
26. PALERMO G, Bizzarri FP, Scarciglia E, Sacco E, et al
    The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
    Int J Urol. 2024;31:1423-1428.
    

    >> Share

    
    
27. SASAKI Y, Fukuta K, Kadoriku F, Daizumoto K, et al
    Retroperitoneal cutaneous ureterostomy following radical cystectomy: A multicenter comparative study of robotic versus open surgery.
    Int J Urol. 2024;31:1408-1413.
    

    >> Share

    
    
28. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    

    >> Share

    
    November 2024
29. NAKAMURA Y, Ishikawa Y, Kobayashi M, Fujiwara M, et al
    Location-specific diagnostic efficiency of photodynamic diagnosis-guided biopsy in bladder mapping biopsies.
    Int J Urol. 2024;31:1263-1268.
    

    >> Share

    
    
30. YOSHIDA S, Maezawa Y, Ishihara K, Inoue N, et al
    Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases.
    Int J Urol. 2024;31:1234-1240.
    

    >> Share

    
    October 2024
31. HARA T, Suzuki K, Okada K, Chiba K, et al
    Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
    Int J Urol. 2024;31:1168-1170.
    

    >> Share

    
    September 2024
32. FUKUOKAYA W, Miki J, Taoka R, Saito R, et al
    Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer.
    Int J Urol. 2024 Sep 18. doi: 10.1111/iju.15585.
    

    >> Share

    
    August 2024
33. YAMANE H, Morizane S, Honda M, Muraoka K, et al
    Preoperative risk stratification models after radical cystectomy for bladder cancer: A multi-center study.
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15560.
    

    >> Share

    
    
34. GIUDICE GC, Sonpavde GP
    Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
    Int J Urol. 2024;31:943-944.
    

    >> Share

    
    
35. CHENG LJ, Kim J, Mukherjee A, Milloy N, et al
    Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
    Int J Urol. 2024;31:933-943.
    

    >> Share

    
    
36. SHINDO T
    Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:867-868.
    

    >> Share

    
    
37. KIKUCHI E, Hayakawa N, Nakayama M, Uno M, et al
    J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:859-867.
    

    >> Share

    
    
38. TAOKA R, Sugimoto M
    A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review.
    Int J Urol. 2024;31:846-851.
    

    >> Share

    
    
39. NOHARA T, Takimoto A, Shinzawa R, Kurauchi D, et al
    Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
    Int J Urol. 2024;31:891-898.
    

    >> Share

    
    July 2024
40. URABE F, Suzuki H, Iwatani K, Kimura T, et al
    Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
    

    >> Share

    
    
41. KIKUCHI E, Hayakawa N
    Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
    

    >> Share

    
    
42. HATTORI Y, Fujiwara T, Hagimoto H, Kokubun H, et al
    Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15524.
    

    >> Share

    
    
43. YASUDA Y, Numao N, Fujiwara R, Takemura K, et al
    Surgical outcomes and predictive value for major complications of robot-assisted radical cystectomy of real-world data in a single institution in Japan.
    Int J Urol. 2024;31:724-729.
    

    >> Share

    
    
44. ASAKAWA K, Waratani M, Massey O, Holbrook T, et al
    Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
    Int J Urol. 2024;31:730-738.
    

    >> Share

    
    June 2024
45. FU H, Hillman E, Talluri S, Liang L, et al
    Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
    Int J Urol. 2024;31:646-652.
    

    >> Share

    
    
46. HARA T, Matsushita Y, Harada K, Fujimoto N, et al
    Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
    Int J Urol. 2024;31:696-698.
    

    >> Share

    
    
47. UEMURA K, Ito H, Jikuya R, Kondo T, et al
    Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Int J Urol. 2024;31:678-684.
    

    >> Share

    
    
48. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
    Int J Urol. 2024;31:628-636.
    

    >> Share

    
    May 2024
49. MITSUI Y, Okawa M, Hori S, Uetani M, et al
    Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
    

    >> Share

    
    
50. MIKI J, Fukuokaya W, Taoka R, Saito R, et al
    Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
    

    >> Share

    
    
51. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    

    >> Share

    
    
52. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    

    >> Share

    
    
53. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    

    >> Share

    
    
54. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    

    >> Share

    
    
55. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    

    >> Share

    
    
56. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    

    >> Share

    
    
57. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    

    >> Share

    
    April 2024
58. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
    

    >> Share

    
    
59. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
    Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
    

    >> Share

    
    
60. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
    Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
    Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
    

    >> Share

    
    
61. LUO HL
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:421.
    

    >> Share

    
    
62. TAOKA R, Sugimoto M
    Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:418-419.
    

    >> Share

    
    
63. HIYAMA Y
    Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:437.
    

    >> Share

    
    
64. URABE F
    Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:420.
    

    >> Share

    
    
65. HAYAKAWA N, Kikuchi E
    Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:402-403.
    

    >> Share

    
    
66. SAZUKA T
    Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:401-402.
    

    >> Share

    
    
67. TAGUCHI S
    Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Int J Urol. 2024;31:348.
    

    >> Share

    
    
68. SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
    Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
    Int J Urol. 2024;31:370-378.
    

    >> Share

    
    
69. KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
    Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:430-437.
    

    >> Share

    
    
70. SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
    Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
    Int J Urol. 2024;31:386-393.
    

    >> Share

    
    
71. YU TY, Wang HJ, Sung MT, Chuang YC, et al
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:410-418.
    

    >> Share

    
    
72. NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
    The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
    Int J Urol. 2024;31:394-401.
    

    >> Share

    
    
73. URABE F, Ito K, Kimura T
    Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
    Int J Urol. 2024;31:452.
    

    >> Share

    
    March 2024
74. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    

    >> Share

    
    
75. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    

    >> Share

    
    
76. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    

    >> Share

    
    February 2024
77. KONDO T
    Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:133.
    

    >> Share

    
    
78. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
    Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:125-132.
    

    >> Share

    
    January 2024
79. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    

    >> Share

    
    
80. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    

    >> Share

    
    
81. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
    Clinical features and oncological outcomes of bladder cancer microsatellite instability.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
    

    >> Share

    
    
82. NAKAMOTO T, Yoshida T
    Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:90.
    

    >> Share

    
    
83. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
    Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Int J Urol. 2024;31:25-31.
    

    >> Share

    
    
84. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
    Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Int J Urol. 2024;31:32-38.
    

    >> Share

    
    
85. JUE JS, Alameddine M, Armenakas NA
    Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:89.
    

    >> Share

    
    December 2023
86. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    

    >> Share

    
    
87. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    

    >> Share

    
    
88. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    

    >> Share

    
    
89. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    

    >> Share

    
    
90. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    

    >> Share

    
    November 2023
91. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    

    >> Share

    
    
92. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    

    >> Share

    
    
93. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    

    >> Share

    
    
94. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    

    >> Share

    
    
95. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    

    >> Share

    
    
96. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    

    >> Share

    
    October 2023
97. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    

    >> Share

    
    
98. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    

    >> Share

    
    
99. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    

    >> Share

    
    
100. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
     Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
     Int J Urol. 2023;30:853-858.
     

     >> Share

     
     September 2023
101. KIKUCHI E, Hayakawa N
     Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
     Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
     

     >> Share

     
     
102. FUKUSHIMA H
     Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
     Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
     

     >> Share

     
     
103. SZARVAS T
     Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
     Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
     

     >> Share

     
     
104. SATO T, Sano T, Kawamura S, Ikeda Y, et al
     Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
     Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
     

     >> Share

     
     
105. KIKUCHI E, Hayakawa N
     Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
     Int J Urol. 2023;30:786-787.
     

     >> Share

     
     
106. HARA T, Furukawa J, Okamura Y, Bando Y, et al
     The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
     Int J Urol. 2023;30:779-786.
     

     >> Share

     
     
107. TOMISAKI I, Harada M, Sakano S, Terado M, et al
     Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
     Int J Urol. 2023;30:738-745.
     

     >> Share

     
     
108. ITO K, Kita Y, Kobayashi T
     Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
     Int J Urol. 2023;30:696-703.
     

     >> Share

     
     
109. GOTO Y
     Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
     Int J Urol. 2023;30:704.
     

     >> Share

     
     August 2023
110. GOTO Y
     Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
     Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
     

     >> Share

     
     
111. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
     Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
     Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
     

     >> Share

     
     
112. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
     Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
     Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
     

     >> Share

     
     
113. GOTO Y
     Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:647-648.
     

     >> Share

     
     
114. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
     Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:634-647.
     

     >> Share

     
     
115. KONDO T
     Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:657.
     

     >> Share

     
     
116. SAZUKA T
     Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:658.
     

     >> Share

     
     
117. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
     Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:649-657.
     

     >> Share

     
     July 2023
118. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
     Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
     Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
     

     >> Share

     
     
119. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
     Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
     Int J Urol. 2023;30:579-584.
     

     >> Share

     
     
120. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
     Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
     Int J Urol. 2023;30:572-578.
     

     >> Share

     
     May 2023
121. LIU Z, Leow JJ, Yong DZP
     Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
     Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
     

     >> Share

     
     
122. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
     Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
     Int J Urol. 2023;30:471-472.
     

     >> Share

     
     
123. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
     Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
     Int J Urol. 2023;30:464-471.
     

     >> Share

     
     April 2023
124. MASTROIANNI R, Torregiani G, Simone G
     Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
     Int J Urol. 2023;30:373-374.
     

     >> Share

     
     
125. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
     Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
     Int J Urol. 2023;30:366-373.
     

     >> Share

     
     March 2023
126. MATSUMOTO K
     Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
     Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
     

     >> Share

     
     
127. MOEEN AM
     Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
     Int J Urol. 2023;30:270-271.
     

     >> Share

     
     
128. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
     Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
     Int J Urol. 2023;30:258-263.
     

     >> Share

     
     
129. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
     Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
     Int J Urol. 2023;30:328-330.
     

     >> Share

     
     
130. SINGH A, Kayina CA, Naik N, Ganesh V, et al
     Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
     Int J Urol. 2023;30:264-270.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share